ReviewDrug design, development and therapy2026
Proteomics in Antitumor Drug Target Discovery, Toxicity, Resistance, and Precision Oncology.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteomics, the comprehensive study of protein expression, localization, and modifications, has evolved from a fundamental research tool into a key complementary layer to genomics in antitumor drug development and precision oncology. This review highlights its multi-dimensional applications, including differential, chemical, and post-translational modification proteomics, for drug-target discovery and mechanism-of-action elucidation. It further discusses proteomics strategies, such as mass spectrometry-based quantitative approaches, protein microarray and single-cell proteomics, which enable the profiling of adverse drug reactions, the dissection of resistance mechanisms, and the advancement of precision oncology. To date, the translational maturity of these applications is uneven: proteomic biomarkers have entered prospective trials and informed molecular tumor board recommendations in selected Clinical Laboratory Improvement Amendments (CLIA) certified settings, whereas de novo proteomics-derived drug targets remain largely at the preclinical stage. By bridging basic research and clinical practice, proteomics provides a scientific framework that facilitates drug development and informs clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.